Almost At The Phase III Finish Line, Lilly Cuts Arzoxifene Losses

Lilly has decided not to submit the NDA for its osteoporosis drug arzoxifene after Phase III data showed the drug fell short on key secondary outcome measures, the firm announced Aug. 18